The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•27 February 2026•

1 min read

UroGen Pharma Announces Positive Clinical Trial Results for Bladder Cancer Treatment ZUSDURI

Key Facts

1ZUSDURI™ achieved durable complete responses in patients with recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC).

UroGen Pharma Ltd. (URGN) has announced positive clinical data from its pivotal ENVISION trial for ZUSDURI™ (UGN-102). The drug achieved durable complete responses in patients suffering from recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC). According to the report, the results demonstrated significant efficacy across various risk groups as classified by the EORTC. The company plans to present a detailed recurrence score analysis at the upcoming ASCO-GU 2026 symposium. These findings support ZUSDURI’s potential as a primary treatment option, marking a significant regulatory milestone for the company. Investors view this development as a major catalyst for UroGen's oncology pipeline and future commercial prospects.